Analysis of the Measurement Characteristics of Inflammatory Bowel Disease Patient-reported Outcomes Measurement Scale

doi:10.12114/j.issn.1007-9572.2023.0197

Abstract

Abstract:

Background

The reported outcome level of patients with inflammatory bowel disease (IBD) has received attention. There are few mature outcome scales with Chinese cultural characteristics for patients with IBD, and the developed scales need strict evaluation.

Objective

To analyze and evaluate the measurement properties of the Inflammatory Bowel Disease Patient-Reported Outcome Measurement Scale〔PROISCD-IBD (V1.0) 〕, to provide basis for scientific evaluation of reported outcomes in patients with IBD.

Methods

From October 2020 to January 2022, PROISCD-IBD (V1.0) was used to detect 274 IBD patients who were treated in the Outpatient and Inpatient Departments of Gastroenterology in the First Affiliated Hospital of Kunming Medical University and the Affiliated Hospital of Guangdong Medical University. PROISCD IBD (V1.0) consisted of 1 commonality module and 1 IBD specific module (TIBD) . The commonality module had 30 items, which were divided into 4 domains of physical health (PHD) , mental health (MHD) , social health (SHD) , and spiritual/belief health (SBD) . TIBD covered four aspects of digestive system symptoms (DSS) , extraintestinal symptom (EXS) , special psychological symptoms (SPP) , and treatment side effects (TSE) . Cronbach's α coefficient and split-half coefficient were used to test the reliability. Correlation coefficient method, exploratory factor analysis and structural equation model were used to analyze the structural validity. Clinical validity of each domain was analyzed using t test.

Results

The Cronbach's α coefficients of PHD, MHD, SHD, SBD and TIBD of PROISCD-IBD (V1.0) were 0.732, 0.838, 0.781, 0.673 and 0.884, respectively. Cronbach's α coefficient of total scale was 0.932. The half-score coefficients of PHD, MHD, SHD, SBD and TIBD were 0.669, 0.859, 0.610, 0.494 and 0.795, respectively, and the half-score reliability of the total scale was 0.879. Correlation analysis showed that the phase coefficients of PHD, MHD, SHD and SBD scores and commonality module score were all >0.6 (P<0.05) . Three principal components were extracted from exploratory factor analysis, and the cumulative variance contribution rate was 58.05%. Structural equation model showed that χ²/df=2.568, root-mean-square error of approximation (RMSEA) =0.076, normed fit index (NFI) =0.677, non-normed fit index (NNFI) =0.774, comparative fit index (CFI) =0.772, incremental fit index (IFI) =0.774, SRMR=0.103 1. IBD patients were divided into active stage (n=90) and remission stage (n=184) according to clinical stages. The total scores of various domains, common modules, TIBD and scale in remission stage were higher than those in active stage (P<0.05) .

Conclusion

PROISCD-IBD (V1.0) has good reliability and validity for reporting outcome measures in patients with IBD.

Key words: Inflammatory bowel diseases, Patient reported outcome measures, Reliability, Validity, Structural equation model

摘要：

背景

炎症性肠病（IBD）患者报告结局水平受到关注，目前少有成熟且具有我国文化特点的IBD患者报告结局量表，已开发出的量表需要经过严格的考评。

目的

对炎症性肠病患者报告结局测定量表〔PROISCD-IBD（V1.0）〕的测量学特性进行分析评价，为科学测评IBD患者报告结局提供依据。

方法

使用PROISCD-IBD（V1.0）对2020年10月—2022年1月在昆明医科大学第一附属医院和广东医科大学附属医院消化门诊及住院部就诊的274例IBD患者的报告结局进行测定。PROISCD-IBD（V1.0）包括1个共性模块和1个IBD特异模块（TIBD）。共性模块共有30个条目，条目又分为4个领域：身体健康（PHD）、心理健康（MHD）、社会健康（SHD）、精神/信仰健康（SBD）。TIBD涵盖4个侧面，依次为消化系统症状（DSS）、肠外症状（EXS）、特殊心理（SPP）、治疗副作用（TSE）。全量表共有44个条目。采用Cronbach's α系数和分半系数对信度进行测定；采用相关系数法、探索性因子分析法和结构方程模型分析结构效度；采用t检验分析各领域的临床效度。

结果

PROISCD-IBD（V1.0）的PHD、MHD、SHD、SBD以及TIBD 5个领域的Cronbach's α系数分别为0.732、0.838、0.781、0.673、0.884，总量表的Cronbach's α系数为0.932；PHD、MHD、SHD、SBD以及TIBD 5个领域的分半系数分别为0.669、0.859、0.610、0.494、0.795，总量表的分半信度为0.879。相关性分析显示，PHD、MHD、SHD和SBD领域得分与共性模块得分的相系数均>0.6（P<0.05）。探索性因子分析共提取出3个主成分，累积方差贡献率为58.047%。结构方程模型显示，χ²/df=2.568，近似误差均方（RMSEA）=0.076，规范拟合指数（NFI）=0.677，不规范拟合指数（NNFI）=0.774，比较拟合指数（CFI）=0.772，增值拟合指数（IFI）=0.774，标准化根均方残差（SRMR）=0.103 1。IBD患者按照临床分期分为活动期（n=90）和缓解期（n=184），缓解期患者各领域、共性模块、TIBD以及量表总分均高于活动期患者（P<0.05）。

结论

PROISCD-IBD（V1.0）的信度和效度较好，可用于IBD患者报告结局测定。

关键词: 炎性肠疾病, 患者报告结局评价, 信度, 效度, 结构方程模型

LUO Na,RUAN Yanqin,LEI Pingguang, et al. Analysis of the Measurement Characteristics of Inflammatory Bowel Disease Patient-reported Outcomes Measurement Scale[J]. Chinese General Practice, 2023, 26(36): 4602-4607. DOI: 10.12114/j.issn.1007-9572.2023.0197.
罗娜,阮艳琴,雷平光等. 炎症性肠病患者报告结局测定量表的测量学特性分析[J]. 中国全科医学, 2023, 26(36): 4602-4607. DOI: 10.12114/j.issn.1007-9572.2023.0197.

Figures/Tables 5

References 20

[1]	中国医药教育协会炎症性肠病专业委员会. 中国炎症性肠病生物制剂治疗专家建议（试行）[J]. 中华消化病与影像杂志（电子版)，2021,11(6):244-256.
[2]	于冰，李信. 炎症性肠病发病机制研究进展[J]. 蛇志，2020,32(1):114-116. DOI：10.3969/j.issn.1001-5639.2020.01.038.
[3]	NG S C, SHI H Y, HAMIDI N，et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century：a systematic review of population-based studies[J]. Lancet，2017,390(10114):2769-2778. DOI：10.1016/S0140-6736(17)32448-0.
[4]	何琼，李建栋. 炎症性肠病流行病学研究进展[J]. 实用医学杂志，2019,35(18):2962-2966. DOI：10.3969/j.issn.1006-5725.2019.18.029.
[5]	KAPLAN G G. The global burden of IBD：from 2015 to 2025[J]. Nat Rev Gastroenterol Hepatol，2015,12(12):720-727. DOI：10.1038/nrgastro.2015.150.
[6]	李惠，李明松. 中国炎症性肠病的挑战和机遇[J]. 现代消化及介入诊疗，2019,24(6):569-572,582. DOI：10.3969/j.issn.1672-2159.2019.06.001.
[7]	LEE J W. Depressive symptoms and quality of life in the patients of inflammatory bowel disease[J]. Gut Liver，2017,11(4):449-450. DOI：10.5009/gnl17227.
[8]	Department of Health and Human Services FDA Center for Drug Evaluation and Research U S, Department of Health and Human Services FDA Center for Biologics Evaluation and Research U S, Department of Health and Human Services FDA Center for Devices and Radiological Health U S. Guidance for industry：patient-reported outcome measures：use in medical product development to support labeling claims：draft guidance[J]. Health Qual Life Outcomes，2006,4:79. DOI：10.1186/1477-7525-4-79.
[9]	卢一，葛畅畅，沈洪，等. 炎症性肠病患者报告结局量表的研究进展[J]. 胃肠病学，2022,27(2):119-123. DOI：10.3969/j.issn.1008-7125.2022.02.012.
[10]	翟云霄，黄婵. 炎症性肠病病人自我报告结局评估工具的研究进展[J]. 全科护理，2022,20(22):3061-3064. DOI：10.12104/j.issn.1674-4748.2022.22.009.
[11]	周云仙. 炎症性肠病生存质量问卷中文版的临床应用研究[D]. 杭州：浙江大学，2006.
[12]	朱丹玲，周云仙，徐红文. 炎症性肠病简明健康量表的汉化及信度效度检验[J]. 中国护理管理，2018,18(12):1630-1634. DOI：10.3969/j.issn.1672-1756.2018.12.010.
[13]	万崇华，高丽，李晓梅，等. 慢性病患者生命质量测定量表体系共性模块研制方法（一）——条目筛选及共性模块的形成[J]. 中国心理卫生杂志，2005,19(11):723-726. DOI：10.3321/j.issn:1000-6729.2005.11.002.
[14]	张传猛，黄志文，万崇华，等. 慢性病患者报告结局测定量表体系之冠心病量表的研制及反应度评价[J]. 中华现代护理杂志，2018,24(17):1991-1995. DOI：10.3760/cma.j.issn.1674-2907.2018.17.002.
[15]	万崇华，巫小玉，刘钰曦，等. 慢性病患者生命质量测定量表体系第2版QLICD（V2.0）研究与应用现状[J]. 广东医科大学学报，2022,40(3):243-249.
[16]	吴开春，梁洁，冉志华，等. 炎症性肠病诊断与治疗的共识意见（2018年·北京）[J]. 中国实用内科杂志，2018,38(9):796-813. DOI：10.19538/j.nk2018090106.
[17]	吴永泽，王文绢. 不同应答等级对likert式量表特性的影响[J]. 中国慢性病预防与控制，2010,18(2):215-217. DOI：10.16386/j.cjpccd.issn.1004-6194.2010.02.003.
[18]	VAN DER STEEG A F W, DE VRIES J, ROUKEMA J A. Quality of life and health status in breast carcinoma[J]. Eur J Surg Oncol EJSO，2004,30(10):1051-1057. DOI：10.1016/j.ejso.2004.07.003.
[19]	欧金清，雷平光，任丹丹，等. 脂肪肝患者生命质量量表的测量学特性评价[J]. 卫生软科学，2020,34(8):36-40. DOI：10.3969/j.issn.1003-2800.2020.08.008.
[20]	刘保延. 患者报告结局的测量：原理、方法与应用[M]. 北京：人民卫生出版社，2011：168.

领域	Cronbach's α系数	分半系数	领域	Cronbach's α系数	分半系数
PHD	0.732	0.669	SBD	0.673	0.494
基本机能状态	0.629		满意度	0.64
活动能力与受限	0.635		信念/信仰	0.615
精力与不适	0.723		共性模块	0.905	0.752
MHD	0.838	0.856	TIBD	0.884	0.795
认知	0.468		消化系统症状	0.839
正性情绪	0.511		肠外症状	0.600
负性情绪	0.862		特殊心理	0.700
SHD	0.781	0.610	治疗副作用	0.759
人际交往	0.667		总量表	0.932	0.879
社会支持	0.551
社会角色	0.319

领域	Cronbach's α系数	分半系数	领域	Cronbach's α系数	分半系数
PHD	0.732	0.669	SBD	0.673	0.494
基本机能状态	0.629		满意度	0.64
活动能力与受限	0.635		信念/信仰	0.615
精力与不适	0.723		共性模块	0.905	0.752
MHD	0.838	0.856	TIBD	0.884	0.795
认知	0.468		消化系统症状	0.839
正性情绪	0.511		肠外症状	0.600
负性情绪	0.862		特殊心理	0.700
SHD	0.781	0.610	治疗副作用	0.759
人际交往	0.667		总量表	0.932	0.879
社会支持	0.551
社会角色	0.319

条目编号	PHD	MHD	SHD	SBD	TIBD	条目编号	PHD	MHD	SHD	SBD	TIBD
PHD1	0.591^a	0.261^a	0.269^a	0.216^a	0.304^a	SHD7	0.524^a	0.578^a	0.598^a	0.173^a	0.546^a
PHD2	0.599^a	0.296^a	0.317^a	0.172^a	0.266^a	SHD8	0.271^a	0.423^a	0.640^a	0.471^a	0.233^a
PHD3	0.588^a	0.504^a	0.362^a	0.205^a	0.373^a	SBD1	0.162^a	0.214^a	0.247^a	0.529^a	0.165^a
PHD4	0.626^a	0.233^a	0.296^a	0.145^a	0.579^a	SBD2	0.066	0.176^a	0.253^a	0.613^a	0.017
PHD5	0.705^a	0.534^a	0.301^a	0.226^a	0.616^a	SBD3	0.329^a	0.368^a	0.392^a	0.645^a	0.290^a
PHD6	0.389^a	0.233^a	0.273^a	0.186^a	0.217^a	SBD4	0.048	0.061	0.076	0.506^a	-0.061
PHD7	0.562^a	0.348^a	0.418^a	0.206^a	0.363^a	SBD5	0.246^a	0.414^a	0.458^a	0.686^a	0.199^a
PHD8	0.630^a	0.531^a	0.325^a	0.170^a	0.443^a	SBD6	0.324^a	0.484^a	0.568^a	0.717^a	0.254^a
MHD1	0.461^a	0.590^a	0.545^a	0.307^a	0.369^a	TIBD1	0.488^a	0.255^a	0.261^a	0.054	0.631^a
MHD2	0.506^a	0.637^a	0.389^a	0.194^a	0.486^a	TIBD2	0.430^a	0.243^a	0.150^a	0.031	0.653^a
MHD3	0.301^a	0.433^a	0.396^a	0.412^a	0.171^a	TIBD3	0.544^a	0.357^a	0.238^a	0.084	0.709^a
MHD4	0.386^a	0.684^a	0.420^a	0.235^a	0.402^a	TIBD4	0.404^a	0.287^a	0.297^a	0.109	0.659^a
MHD5	0.485^a	0.826^a	0.552^a	0.286^a	0.521^a	TIBD5	0.382^a	0.292^a	0.319^a	0.116	0.637^a
MHD6	0.490^a	0.837^a	0.552^a	0.338^a	0.510^a	TIBD6	0.485^a	0.374^a	0.377^a	0.209^a	0.732^a
MHD7	0.403^a	0.761^a	0.456^a	0.293^a	0.492^a	TIBD7	0.312^a	0.205^a	0.186^a	0.020	0.409^a
MHD8	0.477^a	0.703^a	0.665^a	0.559^a	0.410^a	TIBD8	0.547^a	0.459^a	0.403^a	0.114	0.666^a
SHD1	0.440^a	0.582^a	0.711^a	0.481^a	0.425^a	TIBD9	0.360^a	0.362^a	0.314^a	0.096	0.462^a
SHD2	0.193^a	0.300^a	0.551^a	0.331^a	0.154^a	TIBD10	0.498^a	0.507^a	0.425^a	0.203^a	0.761^a
SHD3	0.244^a	0.378^a	0.616^a	0.372^a	0.169^a	TIBD11	0.411^a	0.550^a	0.437^a	0.247^a	0.648^a
SHD4	0.244^a	0.397^a	0.695^a	0.449^a	0.221^a	TIBD12	0.403^a	0.456^a	0.292^a	0.198^a	0.603^a
SHD5	0.285^a	0.405^a	0.708^a	0.482^a	0.285^a	TIBD13	0.453^a	0.570^a	0.465^a	0.304^a	0.672^a
SHD6	0.438^a	0.499^a	0.591^a	0.140^a	0.465^a	TIBD14	0.337^a	0.459^a	0.427^a	0.189^a	0.583^a

条目编号	PHD	MHD	SHD	SBD	TIBD	条目编号	PHD	MHD	SHD	SBD	TIBD
PHD1	0.591^a	0.261^a	0.269^a	0.216^a	0.304^a	SHD7	0.524^a	0.578^a	0.598^a	0.173^a	0.546^a
PHD2	0.599^a	0.296^a	0.317^a	0.172^a	0.266^a	SHD8	0.271^a	0.423^a	0.640^a	0.471^a	0.233^a
PHD3	0.588^a	0.504^a	0.362^a	0.205^a	0.373^a	SBD1	0.162^a	0.214^a	0.247^a	0.529^a	0.165^a
PHD4	0.626^a	0.233^a	0.296^a	0.145^a	0.579^a	SBD2	0.066	0.176^a	0.253^a	0.613^a	0.017
PHD5	0.705^a	0.534^a	0.301^a	0.226^a	0.616^a	SBD3	0.329^a	0.368^a	0.392^a	0.645^a	0.290^a
PHD6	0.389^a	0.233^a	0.273^a	0.186^a	0.217^a	SBD4	0.048	0.061	0.076	0.506^a	-0.061
PHD7	0.562^a	0.348^a	0.418^a	0.206^a	0.363^a	SBD5	0.246^a	0.414^a	0.458^a	0.686^a	0.199^a
PHD8	0.630^a	0.531^a	0.325^a	0.170^a	0.443^a	SBD6	0.324^a	0.484^a	0.568^a	0.717^a	0.254^a
MHD1	0.461^a	0.590^a	0.545^a	0.307^a	0.369^a	TIBD1	0.488^a	0.255^a	0.261^a	0.054	0.631^a
MHD2	0.506^a	0.637^a	0.389^a	0.194^a	0.486^a	TIBD2	0.430^a	0.243^a	0.150^a	0.031	0.653^a
MHD3	0.301^a	0.433^a	0.396^a	0.412^a	0.171^a	TIBD3	0.544^a	0.357^a	0.238^a	0.084	0.709^a
MHD4	0.386^a	0.684^a	0.420^a	0.235^a	0.402^a	TIBD4	0.404^a	0.287^a	0.297^a	0.109	0.659^a
MHD5	0.485^a	0.826^a	0.552^a	0.286^a	0.521^a	TIBD5	0.382^a	0.292^a	0.319^a	0.116	0.637^a
MHD6	0.490^a	0.837^a	0.552^a	0.338^a	0.510^a	TIBD6	0.485^a	0.374^a	0.377^a	0.209^a	0.732^a
MHD7	0.403^a	0.761^a	0.456^a	0.293^a	0.492^a	TIBD7	0.312^a	0.205^a	0.186^a	0.020	0.409^a
MHD8	0.477^a	0.703^a	0.665^a	0.559^a	0.410^a	TIBD8	0.547^a	0.459^a	0.403^a	0.114	0.666^a
SHD1	0.440^a	0.582^a	0.711^a	0.481^a	0.425^a	TIBD9	0.360^a	0.362^a	0.314^a	0.096	0.462^a
SHD2	0.193^a	0.300^a	0.551^a	0.331^a	0.154^a	TIBD10	0.498^a	0.507^a	0.425^a	0.203^a	0.761^a
SHD3	0.244^a	0.378^a	0.616^a	0.372^a	0.169^a	TIBD11	0.411^a	0.550^a	0.437^a	0.247^a	0.648^a
SHD4	0.244^a	0.397^a	0.695^a	0.449^a	0.221^a	TIBD12	0.403^a	0.456^a	0.292^a	0.198^a	0.603^a
SHD5	0.285^a	0.405^a	0.708^a	0.482^a	0.285^a	TIBD13	0.453^a	0.570^a	0.465^a	0.304^a	0.672^a
SHD6	0.438^a	0.499^a	0.591^a	0.140^a	0.465^a	TIBD14	0.337^a	0.459^a	0.427^a	0.189^a	0.583^a

条目编号及简述	因子载荷系数
条目编号及简述	主成分1	主成分2	主成分3
IBD1大便次数频繁	0.747
IBD2大便带有脓血	0.747
IBD4粪便和尿渗出	0.682
IBD3腹部不适	0.653
IBD5肛周疼痛	0.631
IBD6排便又排不尽	0.623
IBD10害怕找不到洗手间	0.614
IBD13苦恼服药或肠镜检查		0.863
IBD12饮食限制		0.737
IBD14药物副作用		0.678
IBD11影响恋爱或婚姻生活		0.619
IBD8头晕、心慌、乏力			0.780
IBD9肠外症状			0.759
IBD7发热
特征根	3.606	2.707	1.814
方差贡献率（%）	25.756	19.336	12.956
累积方差贡献率（%）	25.756	45.091	58.047